Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells

Biochemical and Biophysical Research Communications

Volumn 396, Issue 2, 2010, Pages 299-303

  Hong, Wei ^a   Chen, Linfeng ^b   Li, Juan ^a   Yao, Zhi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Corepressor; MAPK; Nuclear hormone receptor; Tamoxifen

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR RECEPTOR COREPRESSOR; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; GROWTH INHIBITION; GROWTH RATE; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN TRANSPORT; RECEPTOR BINDING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BUTADIENES; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRILES; NUCLEAR RECEPTOR CO-REPRESSOR 2; PROTEIN KINASE INHIBITORS; TAMOXIFEN;

EID: 77952740909     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.04.085     Document Type: Article

References (29)

1. Wintermantel T.M., Elzer J., Herbison A.E., Fritzemeier K.H., and Schütz G. Genetic dissection of estrogen receptor signaling in vivo. Ernst Schering Found Symp. Proc. 1 (2006) 25-44
2. Cheskis B.J., Greger J.G., Nagpal S., and Freedman L.P. Signaling by estrogens. J. Cell Physiol. 213 (2007) 610-617
3. Marino M., Galluzzo P., and Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr. Genomics 7 (2006) 497-508
4. Klinge C.M., Jernigan S.C., Mattingly K.A., Risinger K.E., and Zhang J. Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors. J. Mol. Endocrinol. 33 (2004) 387-410
5. Smith C.L., and O'Malley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25 (2004) 45-71
6. Madak-Erdogan Z., Kieser K.J., Kim S.H., Komm B., Katzenellenbogen J.A., and Katzenellenbogen B.S. Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol. Endocrinol. 22 (2008) 2116-2127
7. Atanaskova N., Keshamouni V.G., Krueger J.S., Schwartz J.A., Miller F., and Reddy K.B. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 21 (2002) 4000-4008
8. Cascio S., Bartella V., Garofalo C., Russo A., Giordano A., and Surmacz E. Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells. J. Biol. Chem. 282 (2007) 3498-3506
9. Klotz D.M., Hewitt S.C., Ciana P., Raviscioni M., Lindzey J.K., Foley J., Maggi A., DiAugustine R.P., and Korach K.S. Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J. Biol. Chem. 277 (2002) 8531-8537
10. R.S. Thomas, N. Sarwar, F. Phoenix, R.C. Coombes, S. Ali, Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity, J. Mol. Endocrinol. 40 (2008) 173-184.
11. Bhat-Nakshatri P., Wang G., Appaiah H., Luktuke N., Carroll J.S., Geistlinger T.R., Brown M., Badve S., Liu Y., and Nakshatri H. AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. Mol. Cell. Biol. 28 (2008) 7487-7503
12. Cheung K.L. Endocrine therapy for breast cancer: an overview. Breast 16 (2007) 327-343
13. Utsumi T., Kobayashi N., and Hanada H. Recent perspectives of endocrine therapy for breast cancer. Breast Cancer 14 (2007) 194-199
14. Sharma D., Saxena N.K., Davidson N.E., and Vertino P.M. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 66 (2006) 6370-6378
15. O'Malley B.W., and Kumar R. Nuclear receptor coregulators in cancer biology. Cancer Res. 69 (2009) 8217-8222
16. O'Malley B.W., and McKenna N.J. Coactivators and corepressors: what's in a name?. Mol. Endocrinol. 22 (2008) 2213-2214
17. Peterson T.J., Karmakar S., Pace M.C., Gao T., and Smith C.L. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity. Mol. Cell. Biol. 27 (2007) 5933-5948
18. Musgrove E.A., and Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9 (2009) 631-643
19. Riggins R.B., Schrecengost R.S., Guerrero M.S., and Bouton A.H. Pathways to tamoxifen resistance. Cancer Lett. 256 (2007) 1-24
20. Chang H.L., Sugimoto Y., Liu S., Ye W., Wang L.S., Huang Y.W., and Lin Y.C. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Anticancer Res. 26 (2006) 1773-1784
21. Rotolo S., Ceccarelli S., Romano F., Frati L., Marchese C., and Angeloni A. Silencing of keratinocyte growth factor receptor restores 5-fluorouracil and tamoxifen efficacy on responsive cancer cells. PLoS One 3 (2008) e2528
22. Sarvilinna N., Eronen H., Miettinen S., Vienonen A., and Ylikomi T. Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells. Int. J. Cancer 118 (2006) 832-840
23. Graham J.D., Bain D.L., Richer J.K., Jackson T.A., Tung L., and Horwitz K.B. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?. J. Steroid Biochem. Mol. Biol. 74 (2000) 255-259
24. Lu S., Jenster G., and Epner D.E. Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol. Endocrinol. 14 (2000) 753-760
25. Hong W., Chen L., Liu Y., and Gao W. ATP hydrolysis is essential for Bag-1M-mediated inhibition of the DNA binding by the glucocorticoid receptor. Biochem. Biophys. Res. Commun. 390 (2009) 77-81
26. Hong W., Baniahmad A., Li J., Chang C., Gao W., and Liu Y. Bag-1M inhibits the transactivation of the glucocorticoid receptor via recruitment of corepressors. FEBS Lett. 583 (2009) 2451-2456
27. Hong W., Baniahmad A., Liu Y., and Li H. Bag-1M is a component of the in vivo DNA-glucocorticoid receptor complex at hormone-regulated promoter. J. Mol. Biol. 384 (2008) 22-30
28. Perissi V., Scafoglio C., Zhang J., Ohgi K.A., Rose D.W., Glass C.K., and Rosenfeld M.G. TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes dual CtBP and NCoR/SMRT transcriptional repression checkpoints. Mol. Cell 29 (2008) 755-766
29. Li X., and McDonnell D.P. The transcription factor B-Myb is maintained in an inhibited state in target cells through its interaction with the nuclear corepressors N-CoR and SMRT. Mol. Cell. Biol. 22 (2002) 3663-3673